Therefore, we hypothesized that lycorine may intervene in MASLD by targeting EGFR and thus affecting the PI3K/AKT signaling pathway, and that this ameliorative effect on MASLD was dose-regulated by lycorine. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.